This site is intended for healthcare professionals only

DiabetesontheNet Logo
×

Diabetes &
Primary Care

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

What next after metformin? A GPnotebook Shortcut

While metformin is considered to be the first-line glucose-lowering medication of choice in most cases, the decision of which agent to use as second-line therapy is more complicated and requires tailoring to the individual. The array of drug classes available, and their wide variety of effects – both positive and negative – beyond reducing blood glucose levels can make this challenging. This GPnotebook Shortcut will help guide the choice of agent after metformin to ensure that the benefits outweigh the potential harm.

Recent years have seen a number of new drugs become available for the management of type 2 diabetes, and emerging evidence suggests that many of these agents have benefits beyond their effects on blood glucose control.
Currently, NICE, the American Diabetes Association and the European Association for the Study of Diabetes all recommend metformin as the first-line antidiabetes drug of choice, in conjunction with diet and lifestyle modification. However, if this fails to keep HbA1c at target levels, the question of which medication should be added is more complex.
 
Reminder: What comes BEFORE metformin is also important
Readers are reminded that healthcare professionals play an important role in the management of type 2 diabetes long before they need to prescribe metformin. Specifically, they should confirm the diagnosis of type 2 diabetes (diabetes is commonly misclassified at diagnosis, which can lead to the wrong treatment; see our previous GPnotebook Shortcut on diagnosis). Providing information and support to lose weight and increase physical activity is the first port of call in managing type 2 diabetes, and newly diagnosed individuals may be encouraged to learn that the condition can be put into remission with sufficient and sustained weight loss (Lean et al, 2019). Finally, reduction of other risk factors, such as blood pressure and cholesterol, should also be considered and appropriate medications offered.
 
What next after metformin?
The decision of which agent to add to metformin therapy should be made in collaboration with the person with diabetes and in accordance with their needs. A host of factors need to be considered, including the individual’s health status, priorities, comorbidities and other medications, as well as the new drug’s cautions and contraindications, side effects, and beneficial effects beyond glucose lowering.
With so many factors to consider, the GPnotebook Shortcut overleaf will help guide the choice of agent after metformin to ensure that the benefits outweigh the potential harm.

 


GPnotebook Shortcuts
GPnotebook Shortcuts are a series of easily digestible, bite-sized resources to help clinicians manage their patients in primary care. A full list of Shortcuts can be found here.

GPnotebook Education
GPnotebook Education is an independent educational resource which has been created with primary care professionals in mind and mirrors the daily work in primary care, using multiple patient case studies to cover latest clinical guidance, research and hot topics.

All GPnotebook Education courses provide unbiased, independent content, prepared and presented by fellow healthcare professionals. Visit gpnotebookeducation.com to learn more.

Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 7: 344–55

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.